Laura Yapor, MD
Pulmonary Disease · Glen Ridge, NJNPI 1609355007
Payments from drug & device makers
Across 163 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$709
- Johnson & Johnson$291
- Viatris Specialty LLC$227
- GSK$218
- Lilly USA, LLC$178
- Sanofi$175
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,20097%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 34 | $709 |
| Johnson & Johnson | 17 | $291 |
| Viatris Specialty LLC | 12 | $227 |
| GSK | 15 | $218 |
| Lilly USA, LLC | 10 | $178 |
| Sanofi | 4 | $175 |
| UCB, Inc. | 10 | $150 |
| Grifols USA, LLC | 1 | $149 |
| Corcept Therapeutics | 6 | $145 |
| Philips North America LLC | 7 | $119 |
| Amgen | 7 | $115 |
| Verona Pharma, Inc. | 6 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Xeris Pharmaceuticals, Inc. | 4 | $83 |
| Alvogen Inc | 3 | $58 |
| ANI Pharmaceuticals, Inc. | 3 | $47 |
| Boehringer Ingelheim | 3 | $45 |
| Radius Health, Inc. | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Exact Sciences | 1 | $32 |
| Bayer | 1 | $30 |
| Electromed, Inc. | 2 | $30 |
| Chiesi USA, Inc. | 1 | $28 |
| Insulet Corporation | 1 | $27 |
| Pulmonx Corporation | 1 | $22 |
| Baxter Healthcare | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Averitas Pharma Inc. | 1 | $16 |
| Abbott | 1 | $14 |
| Embecta Corp. | 1 | $14 |
| Insmed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolastin-C Liquid$149
- TEZSPIRE$125
- DUPIXENT$125
- AREXVY$119
How this compares
$3,300 in reported general payments places this provider in the 55th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 216 | $151,609 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $20,739 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $17,724 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,461 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 261 | $8,119 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $4,689 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $4,549 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $4,208 |
| DuleraMometasone/Formoterol | 11 | $4,173 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,801 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $1,571 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,520 |
| Montelukast Sodium | 62 | $830 |
| Fluticasone Propionate | 32 | $517 |
| Prednisone | 78 | $243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $218 | $179,794277 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $709 | $24,53943 claims |
| MerckDulera | $16 | $4,17311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Glen Ridge
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.